Jump to Main Content

FDA Alerts

FDA Approves Obinutuzumab for Previously Untreated Follicular Lymphoma

The Food and Drug Administration granted regular approval to obinutuzumab (GAZYVA®, Genentech, Inc.) in combination with chemotherapy, followed by obinutuzumab monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III, or IV follicular lymphoma.